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Several lines of evidence implicate dysfunction in brain energy production as a key component of bipolar disorder. In
particular, elevated brain lactate levels observed in this condition suggest a shift from aerobic to anaerobic metabolism,
possibly as a result of mitochondrial abnormalities. Most prior imaging studies of brain metabolites were performed in either
euthymic or depressed bipolar patients or compared different populations in different mood states. We sought to measure brain
metaboliteconcentrationsinthesamepatientsinbothmanicandeuthymicstates.Giventhedramaticchangesinclinicalstateof
bipolar disorder patients, we hypothesized that previously observed abnormalities in lactate concentrations in bipolar disorder
might show state dependent changes. In this study 15 patients (mean age 36.1 years) diagnosed with bipolar I disorder
underwent proton magnetic resonance spectroscopy of the anterior cingulate cortex and parieto-occipital cortex during
hospitalization for acute mania (mean Young Mania Rating Scale (YMRS) 22.1). Seven of these subjects returned (mean interval
21.16 months) to have imaging repeated while euthymic (mean YMRS 2.0). A group of age- and gender-matched control
participants (N¼6) were scanned as well. We report that during mania, bipolar disorder subjects had lactate levels comparable
to healthy control subjects but during euthymia these levels were signiﬁcantly reduced. No signiﬁcant change was observed for
other metabolites. These results implicate mood dependent alterations in energy metabolism in the biology of bipolar disorder.
Additionally, this ﬁndinghas potential use asa biomarker for both evaluating novel treatments as well asdiagnostic clariﬁcation
between mood disorders.
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Introduction
Multiple lines of evidence suggest that metabolic dys-
function is a key feature of bipolar disorder (see Stork and
Renshaw
1 and Dager et al.
2 forreview). In particular,disease-
speciﬁc abnormalities of mitochondria and energy production
have been observed in bipolar disorder.
3–5 Although
these investigations have accumulated evidence linking
metabolic dysfunction to the bipolar disorder trait, the role
of metabolic dysfunction in switches between clinical states
of depression, mania and euthymia has never been well
characterized.
Prior studies have compared different mood states in
separate populations of patients with a bipolar disorder
diagnosis. These cross-sectional studies use a design, which
compares populations whose clinical and treatment histories
and prognosis vary widely. Prior longitudinal studies demon-
strated that patients who present with mania and receive a
bipolar disorder diagnosis will have variable clinical courses
with different levels of inter-episode impairment, widely
varying temporal courses and possibly very different eventual
diagnoses.
6,7 Clearly, a longitudinal study design with intra-
subject measures of the same patients in different mood
states would allow better characterization of state related
physiological changes.
Few prior studies of brain metabolism in bipolar disorder
have utilized high ﬁeld magnetic resonance spectroscopy
(MRS), which allows improved characterization of in vivo
neurochemistry over older techniques. In this 4T Proton MRS
study, we measured brain metabolite concentrations, including
lactate,ameasurerelatedtoenergymetabolism,intheanterior
cingulate cortex (ACC) and parietal occipital cortex (POC) in a
cohort of medicated patients with a diagnosis of bipolar
disorder type I. We chose the ACC because it is a region
strongly implicated in the pathophysiology of bipolar disorder.
8
We chose the POC as the comparison region. To increase the
power of our study and minimize medication confounds, we
performed our assessments in a single cohort of patientswhen
they were clinically manic and in the same patients when they
were clinically euthymic. An age and gender matched set of
healthy control (HC) subjects were also scanned using the
same protocol. We hypothesized that given the dramatic
changes in clinical state of bipolar disorder patients, abnorm-
alities in markers of brain metabolism previously observed in
bipolar disorder might show state dependent changes.
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www.nature.com/tpMaterials and methods
Subjects. Subject recruitment and proton MRS imaging
were performed at the McLean Hospital, (Belmont, MA,
USA) as previously described.
9 Following approval by the
Institutional Review Board of McLean Hospital, 39 subjects
diagnosed with bipolar I disorder in a current manic state as
per DSM-IV were recruited from a psychiatric inpatient unit.
Twenty-two HC subjects were recruited concurrently. Diag-
noses were determined by consensus based on structured
clinical interviews for DSM disorders
10 by a trained clinician,
and all available clinical data. Subjects with signiﬁcant
neurological or medical problems, current substance abuse,
or history of substance dependence were excluded.
Tobacco smokers were not excluded from the study. All
patients had negative urine toxicology tests at the time of
scanning. Patients were assessed using the Young Mania
Rating Scale (YMRS), Positive And Negative Syndrome
Scale (PANSS) and Montgomery–Asberg depression rating
scale (MADRS) on scan days. Current medication regimens
were recorded and chlorpromazine (CPZ) equivalents were
calculated for patients taking antipsychotic medications. HC
subjects were assessed using the structured clinical inter-
views for DSM disorders to rule out axis I disorders. None of
the patients met criteria for rapid cycling. Usable data were
obtained from 21 HC and 15 BD subjects. Twenty-two
patients were unable to tolerate the scanning environment
because of their psychiatric condition and were therefore not
included in the study. Two other patients elected to enter the
study but refused the scan after structured clinical interviews
for DSM disorders and symptoms scales were collected.
The bipolar I disorder subjects who did not complete the
study were more symptomatic than those who completed the
study (non-completer average YMRS: 26.9; MADRS: 18.4;
PANSS: 82.0; completer average YMRS: 24.7, MADRS:
11.1, PANSS: 59.6). Patients with bipolar disorder in a
manic phase who completed the 4T MRS scan and symptom
scales were subsequently contacted (between 12–50
months later) for follow-up assessments. These patients
were re-assessed with the same exclusion criteria described
above. At follow-up, all were clinically euthymic and none
met DSM-IV criteria for mania, hypomania or major
depressive episode. Although symptomatology score cutoffs
were not used to deﬁne euthymia for the purposes of
inclusion, the scores recorded at the time of the second scan
suggest subjects were no more than minimally symptomatic
(Table 1). Eight subjects were successfully contacted, met
criteria for inclusion and consented for the study. Seven
subjects were able to complete the follow-up scan and
repeat symptomatology scales. Compared with subjects that
successfully completed the follow-up study, subjects that
completed the ﬁrst scan but were unable to complete the
follow-up study did not differ signiﬁcantly in their distribution
of symptoms at the time of the ﬁrst scan: Completer YMRS
22.1±8.2 versus non-completer YMRS 27±9.3 (P¼0.31),
completer MADRS 12.7±3 versus non-completer MADRS
9.6±3.6 (P¼0.095), completer PANSS: 56.3±13 versus
non-completer PANSS 62.5±14.9 (P¼0.41).
Among the bipolar subjects that completed both manic and
euthymic scans, no patients met DSM-IV criteria for panic
disorder, a diagnosis with known trait differences in brain
lactate responsivity to chemical challenges.
11 Two subjects
met DSM-IV criteria for prior diagnosis of EtOH abuse. In
neither case did the subject meet criteria within the 5 years
before entering the study and neither engaged in daily EtOH
use at any point. One of these two subjects also endorsed
cannabis use that met DSM criteria for abuse over a period of
2weeksadecadebeforeenteringthestudy.Noothersubjects
described substance use that met criteria for abuse or
dependence at any point currently or historically.
Magnetic resonance imaging/MRS scans. Proton MRS
acquisitions were conducted on a 4 Tesla full body magnetic
resonance scanner (Varian/UnityInova, Varian, Palo Alto, CA,
USA), using a 16-rung, single-tuned, volumetric birdcage coil
(Robarts Research Institute, London, Ontario, Canada).
Two-dimensional (2-D) gradient-recalled echo images (12s)
were acquired in three planes to ensure optimal patient
positioning. Manual global shimming of unsuppressed water
signal yielded an unﬁltered global water linewidth of p30Hz.
T1-weighted sagittal images (TE/TR¼6.2/11.4ms, FOV¼24
 24 8cm
3, in-plane resolution¼0.94 1.88mm
2, slice
thickness¼5mm, readout points¼512, ﬂip angle¼111)
and axial images (similar parameters as above, except for
in-plane resolution¼0.94 0.94mm
2, slice thickness¼2.5
mm) were next acquired, allowing for clear differentiation
between cortical gray matter (GM) and white matter and
serving as anatomical guides to positioning MRS voxels.
A2 2 2cm
3 single voxel wasthen placedon theanterior
cingulate cortex. We placed the voxel on midsagittal T1-
weighted images, anterior to the genu of the corpus callosum,
withtheventraledgealignedwiththedorsalcornerofthegenu
(Figure 1), and positioned the voxel on the midline on axial
images. We used a point-resolved spectroscopy sequence
modiﬁed for J-resolved proton (
1H) MRS employing a four-
pulse water suppression enhanced through T1 effects (WET)
sequence.
12
Table 1 Subject demographics and clinical information
Healthy
control
(N¼6)
Bipolar
manic
(N¼7)
Bipolar
euthymic
(N¼7)
Age 35.2±8.1 37.6±10.7 39.7±10.9
Gender 3 M, 3 F 3 M, 4 F 3 M, 4 F
MADRS — 12.7±2.9 3.71±2.7
YMRS — 22.1±8.2 2.0±3.2
PANSS — 56.3±13.0 35.4±3.7
Anticonvulsants — 5 3
SGAs — 7 5
Lithium — 5 4
CPZ equivalents — 343±154 352.2±437
Benzodiazepines — 5 2
Abbreviations: CPZ, chlorpromazine; F, female; M, male; MADRS,
Montgomery–Asberg Depression Rating Scale; PANSS, Positive and Negative
Syndrome Scale; SGA, second generation antipsychotic, YMRS, Young Mania
Rating Scale.
Mean±s.d. where appropriate.
Numbers in medication rows are the number of subjects whose regimen
includes that class of psychotropic medication. In addition to psychotropic
medications, three bipolar subjects were prescribed other medications
including one patient taking anti-hypertensive medication, one subject taking
a statin, anti-hypertensive medication and oral anti-hyperglycemic medication
and one subject taking a statin and a oral anti-hyperglycemic medication.
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Translational PsychiatryManual shimming within the voxel resulted in water
linewidths p11Hz. Following ﬂip angle, water suppression,
and RF pulse power optimization using automated meth-
ods, the 2-D J-resolved sequence collected 48 TE-stepped
spectrafromthevoxel,withtheechotimerangingfrom30to
500ms in 10-ms increments. Acquisition parameters were
TR¼2.0s, acquisition bandwidth¼2kHz, repetitions¼16,
nominal voxel volume¼8cc and approximate scan
duration¼28min.
This process was repeated on a 2 2 2-cm
3 parieto-
occipital cortex voxel. On midsagittal images, we aligned the
ventraledgeofthevoxelwiththedorsalcornerofthesplenium
of the corpus callosum, covering posterior cingulate and
retrosplenial cortices, and positioned the voxel on the midline
in axial images (Figure 1). As POC spectral quality was
superior, eight repetitions were obtained in B14min. Total
time in the magnet was 75–90min.
MRS data processing and analysis. All MRS
processing was performed blind to diagnosis. Real (not
magnitude) spectra were used (Figure 2). For each voxel, the
24 TE-stepped free-induction decays were zero-ﬁlled to 128
free-induction decay in f1. We used the commercial spectral
ﬁtting package LC Model (version 6.1-4E, Oakville, Ontario,
Canada) to ﬁt every J-resolved spectral extraction within a
bandwidth of 50Hz ( 25 to þ25Hz). We used GAMMA to
generate sets of 48 point-resolved spectroscopy sequence,
TE-stepped spectra ranging from 30 to 500ms in 10-ms
increments. For every metabolite, we ﬁt its spectrum over
50Hz bandwidth ( 25 to þ25Hz; 64 TE points), deriving
the integrated area under the 2-D surface.
12 Spectral regions
outside this range did not contain signiﬁcant metabolite
signal but contributed additional noise. LC Model provides
Cramer–Rao lower bounds (CRLBs), an estimate of the
variance associated with ﬁtting. In our case, each 2-D
spectrum produced 64 CRLBs for each metabolite. These
ranged from o5% in regions of high certainty to 450% in
regions of low certainty. To accurately reﬂect the reliability of
the 2-D-ﬁtting procedure, we determined an average CRLB
value weighted by the signal-to-noise ratio of each spectral
extraction on the basis of the N-acetylaspartate (NAA)
resonance.
9,13 Metabolite values with a CRLB above 25%
were discarded given their poor ﬁt.
The results of LC Model ﬁtting for each metabolite are
reported as arbitrary units. Concentrations of given metabo-
lites are expressed as ratios of the metabolite arbitrary unit/
creatine-phosphocreatine (Cr) arbitrary unit. No statistically
signiﬁcant difference in Cr concentration was found between
BD subjects and HCs.
14
Image segmentation. Tissue segmentation of T1-weighted
images into GM, white matter and cerebrospinal ﬂuid in
each MRS voxel was calculated using Matlab (Natick, MA,
USA) and the SPM toolbox (Cambridge, UK). The percen-
tage of GM in ACC and POC was 56.0±5.7% and
49.1±7.6% (BD-manic), 58.1±4.1% and 53.8±5.1%
(BD-euthymic), 60.3±2.4% and 57.7±2.9% (controls) while
that of white matter was 23.5±3.6% and 38.5±7.8%
(BD-mania), 20.5±4.1% and 35.7±5% (BD-euthymia),
22.0±6.5% and 30.6±3.0% (controls), respectively. There
was no statistically signiﬁcant difference in GM% between
the bipolar patients in the euthymic state and in the manic
state in the ACC (P¼0.44) or POC (P¼0.19). Nor was there
any statistically signiﬁcant difference in GM between the
bipolar patients in the euthymic state and HC subjects in the
ACC (P¼0.26) or POC (P¼0.17).
Statistical analysis. Given the prior literature on metabolic
dysfunction in bipolar disorder and speciﬁc ﬁndings on
lactate,
4 glutamine/glutamate ratio
4,9,13 and NAA
15 in manic
or mixed states, we assessed the effect of mood state (mania
versus euthymia) and voxel location (ACC vs POC) on
glutamine/glutamate, NAA/Cr and lactate/Cr measures using
a General Linear Model analysis ﬁt using the Mixed routine in
SPSS statistical software (SPSS, Chicago, IL, USA.) with
age, gender and GM% as covariates. Main effects and
voxel location by mood state interaction were explored.
Signiﬁcance was ﬁxed at a¼0.05. We examined the effects
of gender and medication (that is, medicated status versus
unmedicated status for benzodiazepines, for lithium, and for
anticonvulsants) on metabolite ratios using one-way analysis
of variances. We calculated correlation coefﬁcients for the
relationships between age, voxel GM% and CPZ equivalents
with metabolite/Cr values. Finally, we examined MADRS,
YMRS and PANSS score correlations with metabolite/Cr
values.
Results
For Lactate/Cr there was a main effect of clinical state
[F(1,5)¼33.296, P¼0.002] but no main effect of voxel
location [F(1,5)¼0.908, P¼0.383]. When a voxel location
  clinical state interaction was incorporated into the model,
there was a main effect of clinical state [F(1,6)¼8.972,
P¼0.026] but no main effect of voxel location [F(1,6)¼0.08,
P¼0.785] nor a voxel location   clinical state interaction
[F(1,6)¼0.001, P¼0.981]. Speciﬁcally, Lac/Cr values were
36% lower in the euthymic state than in the manic state
(Figure 3).
Figure 1 Placement of the anterior cingulate cortex (ACC) (left) and parietal occipital cortex (POC) (right) voxels.
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Translational PsychiatryFor the Gln/Glu ratio there was a main effect of clinical state
[F(1,3)¼10.923, P¼0.043] but no main effect of voxel
location [F(1,4)¼0.067, P¼0.808]. When a voxel location
  clinicalstateinteractionwasincorporatedintothemodel,no
signiﬁcant differences were seen in Gln/Glu ratio between
clinicalstates[F(1,3)¼2.369,P¼0.225],norbyvoxellocation
[F(1,4)¼0.365, P¼0.578] nor was there a voxel location  
clinical state interaction [F(1,1)¼0.465, P¼0.615].
For NAA/Cr there was no main effect of clinical state
[F(1,6)¼4.18, P¼0.090]. There was a signiﬁcant effect of voxel
location with higher NAA levels found in the POC versus ACC
[F(1,6)¼76.298, Po0.001]. When a voxel location   clinical
state interaction was incorporated into the model, no signiﬁcant
differences were seen in NAA for clinical state [F(1,6)¼2.23,
P¼0.188] nor was there a voxel location   clinical state
interaction [F(1,5)¼3.061, P¼0.144]. There remained a
signiﬁcant effect of voxel location [F(1,5)¼70.823, Po0.001].
One-way analysis of variance analysis revealed no statis-
tically signiﬁcant effects on lactate/Cr values by gender or the
use of antipsychotics, benzodiazepines, lithium or antic-
onvulsants. Age, voxel GM% and CPZ equivalents were not
correlated with metabolite/Cr values. YMRS, MADRS and
PANSS scores did not correlate with metabolite/Cr values.
The brain lactate/Cr values for patients in the manic state
(mean0.074±0.040)weresimilartothoseofasetofage-and
gender-matched control subjects (mean 0.070±0.028) but
signiﬁcantly (P¼0.049) lower in patients in the euthymic state
(mean 0.048±0.016) compared with controls (Figure 3).
Discussion
To our knowledge this is the ﬁrst longitudinal
1H-MRS study
across mania and euthymia of patients diagnosed with bipolar
disorder type I. Patients diagnosed with bipolar disorder type I
demonstrated a state related change in brain lactate
concentration with euthymic subjects showing a signiﬁcantly
lower lactate signal compared with the same subjects in a
manic state. When compared with age- and gender-matched
H2OC r A A N o h C
s M M r C Lac
Figure 2 Contourplotsof real two-dimensional(2-D) spectrafromtheanteriorcingulatecortex(ACC)in acontrol(top)andbipolardisorder(BD)subject(bottom).In each
case, the X axis is frequency (F2 in p.p.m.) and the Y axis is J (F1 in Hz). The spectral region from about  35 to þ35Hz is shown. The main metabolite resonances
recognizable in the plots are labeled. Although the lactate resonance is not well-resolved in these plots, its approximate location at 1.33p.p.m. is highlighted. The additional
information available from 2-D magnetic resonance spectroscopy (MRS) allows improved ﬁtting of this metabolite as discussed in the text. Note the variable nature of water
suppression, and of the macromolecule signal proﬁle (highlighted in a box in the top panel) in the two spectra. Lac, lactate; H2O, water; GSH, glutathione; MMs,
macromolecules.
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Translational PsychiatryHCs, bipolar disorder patients in the manic state showed no
abnormality in brain lactate concentration. Euthymic bipolar
disorder patients demonstrated a signiﬁcantly decreased
lactate concentration when compared with a HC population.
The observation that lactate is nearly normal in the manic
state and signiﬁcantly reduced in euthymia is intriguing.
Prior observations in
31P MRS suggest a similar trajectory of
the membrane precursor phosphomonoester (PME) peak
between pathological mood states and euthymia. Kato et al.
3
demonstrated that PME was modestly increased in mania
versus control subjects and that PME decreased to a
signiﬁcantly lower than control level in euthymia. A study by
Kato et al.
16 and a meta-analysis conducted by Yildiz et al.
17
found a similar trajectory in which bipolar patients in the
depressed state have elevated PME while those in a euthymic
state have PME levels decreased compared with controls.
A recent study by Kim et al.
18 of quetiapine in the treatment of
rapid-cycling bipolar disorder demonstrated a signiﬁcant
decrease in brain lactate during treatment with quetiapine. That
study could not differentiate metabolic changes due to quetia-
pineadministrationversuschangesbecauseofimprovementin
clinical state and subjects were not followed to euthymia.
What might be the physiological signiﬁcance of the
observed lactate changes? In synthesizing the growing body
of ﬁndings about metabolic dysfunction in bipolar disorder,
Stork et al.
1 proposed that mitochondrial dysfunction causing
impaired oxidative phosphorylation is a hallmark of bipolar
disorder. In this model, mitochondrial dysfunction results in a
shift to anaerobic metabolism and increased lactate observed
in bipolar disorder in a depressed or mixed-state.
4 This
mitochondrial dysfunction also may result in alterations in
PME levels
3,17 thought to represent changes in phospholipid
membrane metabolism. Kato and Kato
19 hypothesized that
bipolar disorder is characterized by a trait metabolic dysfunc-
tion that is demonstrated in the abnormal ﬁndings observed in
euthymia. They conjectured that the brain’s attempts to
‘correct’ these abnormalities through increased monoaminer-
gic neurotransmission might induce pathological mood states
such as depression or mania. In other words, neither mood
episodes nor euthymia are truly healthy states in bipolar
disorder. Rather, they represent varying degrees of compen-
sation to underlying abnormalities.
In examining the effect of clinical state on other metabolites
it is worth noting that the Gln/Glu ratio demonstrated a
signiﬁcant (P¼0.046) effect of clinical state. This ﬁnding did
not meet criteria for signiﬁcance when corrected for multiple
comparisons (adjusted a¼0.016), nor was there a signiﬁcant
effect of clinical state when state by anatomical region
interaction was incorporated into the model. Nevertheless,
thisresultsuggeststhatGln/Gluratioabnormalitiespreviously
observed in bipolar disorder
9 may in fact vary with clinical
state. This ﬁnding bears further investigation.
The strengths of this study include the investigation of
inpatients who are highly resistant to engage in research
studies, the longitudinal design and the assessment of both
euthymic and manic states in the same individuals, a
challenging task.
20 All of our subjects were scanned on the
same high ﬁeld (4T) magnet at both time points and we have
included a control population. Medication regimens were
relatively consistent at both time points.
Onelimitationofourstudyisasmallsamplesizethatmakes
it difﬁcult to rule out type I errors. This applies both to patients
as well as HC subjects whose small numbers represent an
attempt to provide a match for age and gender to the patient
population. Another limitation is the generalizability of these
ﬁndings. Although manic state scans were all acquired in a
population symptomatic enough to require inpatient hospita-
lization, the patients who were able to complete the manic
state scan were generally less symptomatic than those who
could not complete the scan. Additionally, at the time of the
euthymic state, all subjects were in ongoing psychiatric
treatment, free of substance abuse or dependence and were
able to be contacted and perform the follow-up study as
outpatients. It is possible that these patients may have better
inter-episodefunctioningandbetterprognosistherebylimiting
generalization to the bipolar disorder population as a whole.
Finally, although we cannot rule out an effect of medications
on our ﬁndings, the longitudinal nature of this experiment was
designed to minimize differences in medication regimens at
both time points.
This demonstration of a relationship between metabolic
dysfunction and mood state has implications for both the
diagnosis of bipolar disorder as well as its treatment.
Epidemiological studies demonstrate that at least 20% of
patients hospitalizedforunipolar depression will goon tohave
a diagnosis of bipolar disorder type I.
21 The development of a
biomarker measurable at hospitalization that can differentiate
euthymiainbipolardisorderversusunipolardepressionwould
be of signiﬁcant diagnostic and predictive value. Similar
studies are needed to compare brain lactate in both bipolar
disorderaswellasunipolardepressionacrossdepressiveand
euthymic states.
Figure 3 Brain lactate concentrations measured as lactate/creatinine ratios in
the parietal occipital cortex (POC) and anterior cingulate cortex (ACC) for bipolar
patients in a manic state (left), bipolar patients in a euthymic state (middle), and
healthy control subjects (right). Identical voxel locations in the same subjects are
connectedbygray lines.Thegroupmean(error bars¼s.d.)isshownat theside for
each time point. *P¼0.002; **P¼0.049.
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clinical state will possibly allow evaluation of novel therapies.
Notably, Kim et al.
18 have already performed a study
examining both symptomatology score changes we well as
changes in lactate in response to quetiapine. Although Kim
et al. did not follow patients to euthymia; they did note a
signiﬁcant association between change in lactate level and
clinical response. This ﬁnding may be extended to other
interventions and may allow for the early differentiation of
patientswho willachieve responsefrom thosewho willremain
symptomatic.
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